Philadelphia, United States
Imvax, Inc. is a clinical-stage biotechnology company established in 2015, headquartered in the United States. The company specializes in developing personalized, whole tumor-derived immunotherapies. Its innovative approach uniquely harnesses the complete antigenic profile of a patient's tumor, transforming it into a robust training program for the immune system, aiming for both innate and adaptive immune responses to maximize long-term anti-tumor impacts.
The company's flagship program targets glioblastoma multiforme (GBM), a highly aggressive brain cancer. Additionally, Imvax is expanding its pipeline to include therapies for other solid tumors. These efforts position Imvax within the Biotechnology, Health and Wellness, and Pharmaceutical industries.
Recently, the company secured a $35.00M venture round investment on May 21, 2024, signaling strong confidence in its approach and potential impact in the oncology therapeutics landscape.
